BRAF mutations in canine cancers

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Mochizuki, Hiroyuki ^a   Kennedy, Katherine ^a   Shapiro, Susan G ^a   Breen, Matthew Breen ^a,b  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GLUTAMIC ACID; MITOGEN ACTIVATED PROTEIN KINASE;

AMINO ACID SUBSTITUTION; ANIMAL TISSUE; ARTICLE; BRAF GENE; CODON; COHORT ANALYSIS; CONTROLLED STUDY; DOG DISEASE; ENZYME ACTIVATION; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC CONSERVATION; HUMAN; MALE; NEOPLASM; NONHUMAN; PROSTATE CARCINOMA; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSITIONAL CELL CARCINOMA; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; DNA SEQUENCE; DOG; GENETIC PREDISPOSITION; GENETICS; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; VETERINARY;

CANIS FAMILIARIS;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; BASE SEQUENCE; DOGS; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; SEQUENCE ANALYSIS, DNA;

EID: 84935054101     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129534     Document Type: Article

References (38)

1. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nature Reviews Cancer. 2004; 4(12): 937-947. PMID: 15573115
2. Dhillon A, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007; 26 (22): 3279-3290. PMID: 17496922
3. Roskoski R. RAF protein-serine/threonine kinases: structure and regulation. Biochemical and biophysical research communications. 2010; 399(3): 313-317. doi: 10.1016/j.bbrc.2010.07.092 PMID: 20674547
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002 Jun 27; 417(6892): 949-954. PMID: 12068308
5. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer research. 2002; 62(23): 6997-7000. PMID: 12460918
6. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, et al. BRAF mutation in papillary thyroid carcinoma. Journal of the National Cancer Institute. 2003; 95(8): 625-627. PMID: 12697856
7. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High Prevalence of BRAF Mutations in Thyroid Cancer Genetic Evidence for Constitutive Activation of the RET/PTC-RAS-BRAF Signaling Pathway in Papillary Thyroid Carcinoma. Cancer research. 2003; 63(7): 1454-1457. PMID: 12670889
8. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. The Journal of Clinical Endocrinology & Metabolism. 2003; 88(9):4393-4397.
9. Xing M. BRAF mutation in thyroid cancer. Endocrine-related cancer. 2005; 12(2): 245-262. PMID: 15947100
10. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, et al. BRAF mutations in hairy-cell leukemia. The New England journal of medicine. 2011; 364(24): 2305-2315. doi: 10.1056/ NEJMoa1014209 PMID: 21663470
11. Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. Journal of Investigative Dermatology. 2004; 122(2): 337-341. PMID: 15009714
12. Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. Journal of Investigative Dermatology. 2006; 126(1): 154-160. PMID: 16417231
13. Shelly S, Chien MB, Yip B, Kent MS, Theon AP, McCallan JL, et al. Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas. Mammalian genome: official journal of the International Mammalian Genome Society. 2005; 16(3): 211-217.
14. Fowles J, Denton C, Gustafson D. Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma. Veterinary and comparative oncology. In press.
15. Richter A, Murua Escobar H, Gunther K, Soller JT, Winkler S, Nolte I, et al. RAS gene hot-spot mutations in canine neoplasias. The Journal of heredity. 2005; 96(7): 764-765. PMID: 16251512
16. Campos M, Kool MM, Daminet S, Ducatelle R, Rutteman G, Kooistra HS, et al. Upregulation of the PI3K/Akt pathway in the tumorigenesis of canine thyroid carcinoma. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine. 2014; 28(6): 1814-1823. doi: 10.1111/jvim. 12435 PMID: 25231196
17. Gillard M, Cadieu E, De Brito C, Abadie J, Vergier B, Devauchelle P, et al. Naturally occurring melanomas in dogs as models for non-UV pathways of human melanomas. Pigment cell & melanoma research. 2014 Jan; 27(1): 90-102.
18. Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, et al. Determinants of BRAF mutations in primary melanomas. Journal of the National Cancer Institute. 2003; 95(24): 1878-1890. PMID: 14679157
19. Edwards R, Ward M, Wu H, Medina C, Brose M, Volpe P, et al. Absence of BRAF mutations in UV-protected mucosal melanomas. Journal of medical genetics. 2004; 41(4): 270-272. PMID: 15060100
20. Boulalas L, Zaravinos A, Delakas D, Spandidos DA. Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder. International Journal of Biological Markers. 2009; 24(1): 17-21. PMID: 19404918
21. Schulz WA. Understanding urothelial carcinoma through cancer pathways. International journal of cancer. 2006; 119(7): 1513-1518. PMID: 16557569
22. Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015; 15(1): 25-41. doi: 10.1038/nrc3817 PMID: 25533674
23. LeRoy BE, Northrup N. Prostate cancer in dogs: comparative and clinical aspects. The Veterinary Journal. 2009; 180(2): 149-162. doi: 10.1016/j.tvjl.2008.07.012 PMID: 18786842
24. Cho NY, Choi M, Kim BH, Cho YM, Moon KC, Kang GH. BRAF and KRAS mutations in prostatic adenocarcinoma. International journal of cancer Journal international du cancer. 2006; 119(8): 1858-1862. PMID: 16721785
25. Kollermann J, Albrecht H, Schlomm T, Huland H, Graefen M, Bokemeyer C, et al. Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patients. Oncology letters. 2010; 1(4): 729-732. PMID: 22966370
26. Ren G, Liu X, Mao X, Zhang Y, Stankiewicz E, Hylands L, et al. Identification of frequent BRAF copy number gain and alterations of RAF genes in Chinese prostate cancer. Genes, chromosomes & cancer. 2012; 51(11): 1014-1023.
27. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer cell. 2010; 18(1): 11-22. doi: 10.1016/j.ccr.2010.05.026 PMID: 20579941
28. Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, et al. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer research. 2012; 72(7): 1878-1889. doi: 10.1158/0008-5472.CAN-11-3132 PMID: 22350410
29. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nature medicine. 2010; 16(7): 793-798. doi: 10.1038/nm.2166 PMID: 20526349
30. Wang X-S, Shankar S, Dhanasekaran SM, Ateeq B, Sasaki AT, Jing X, et al. Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer discovery. 2011; 1(1): 35-43. doi: 10.1158/ 2159-8274.CD-10-0022 PMID: 22140652
31. Gao H, Ouyang X, Banach-Petrosky WA, Gerald WL, Shen MM, Abate-Shen C. Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proceedings of the National Academy of Sciences. 2006; 103(39): 14477-14482. PMID: 16973750
32. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nature reviews Clinical oncology. 2013; 10(8): 472-484. doi: 10.1038/nrclinonc.2013.110 PMID: 23836314
33. Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. Journal of Clinical Oncology. 2014; 32(6): 579-586. doi: 10.1200/JCO.2012.45.2011 PMID: 24449238
34. Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. The Lancet. 2012; 380(9839): 358-365. doi: 10.1016/S0140-6736(12)60868-X PMID: 22735384
35. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England Journal of Medicine. 2011; 364 (26): 2507-2516. doi: 10.1056/NEJMoa1103782 PMID: 21639808
36. Follows GA, Sims H, Bloxham DM, Zenz T, Hopper MA, Liu H, et al. Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib. British journal of haematology. 2013; 161(1): 150-153. doi: 10.1111/bjh.12201 PMID: 23278307
37. Haroche J, Cohen-Aubart F, Emile J-F, Arnaud L, Maksud P, Charlotte F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013; 121(9): 1495-1500. doi: 10.1182/blood-2012-07-446286 PMID: 23258922
38. Munoz J, Schlette E, Kurzrock R. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. Journal of Clinical Oncology. 2013; 31(20): e351-e352. doi: 10.1200/JCO.2012.45.7739 PMID: 23733763